B-Lymphoblastic Leukemia / Lymphoma · line 1 · Hyper-CVAD + Rituximab (CD20+) — alternating courses A/B, 8 cycles total
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-HYPER-CVAD-R |
| ID | IND-B-ALL-1L-PH-POS |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-B-ALL |
| Sources | SRC-NCCN-BCELL-2025 |
Notes
STUB. time_critical=true — falls outside FDA non-device CDS carve-out (CHARTER §15.2 C5). Engine додає warning для clinician acknowledgment.
Used By
Algorithms
ALGO-B-ALL-1L- ALGO-B-ALL-1L